NCT01732718View on ClinicalTrials.gov

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 9, 2018

Study Completion Date

January 9, 2018

Conditions
Sickle Cell DiseaseSickle Cell Nephropathy
Interventions
DRUG

Atorvastatin

40 mg tablet by mouth daily for 6 weeks

DRUG

Placebo

Matching placebo tablet by mouth daily for 6 weeks

Trial Locations (1)

27599

UNC School of Medicine Clinical&Translational Research Ctr, Chapel Hill

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT01732718 - Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease | Biotech Hunter | Biotech Hunter